Pushing the treatment envelope for chronic hepatitis C—is more necessarily better?

Is an “à la carte” combination interfero

Is an “à la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?

✍ Thierry Poynard; John McHutchison; Zachary Goodman; Mei-Hsiu Ling; Janice Albrec 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 1 views

Randomized trials have shown the enhancement of efficacy with interferon alfa-2b and ribavirin (IFN-R) in comparison with interferon monotherapy (IFN) as first line treatment of chronic hepatitis C. Further definition of response based on disease, patient, and treatment characteristics is needed to